With stress on analytical testing, toxicity testing, and fill and finish operations, CMOs hope to expand outsourcing to vastly greater levels in many areas.
There are many acquisition targets with a sizable clinical pipeline of cell and gene therapies and mRNA platform, according to the M&A Firepower study from E&Y.
The rising costs of operations within the pharmaceutical sector have become an increasing source of concern for industry leaders throughout the course of 2022.
Biotech startups and their investors are dealing with variety of issues this year, such as the impact of Inflation Reduction Act and slowdown in public markets.
The top decisions on the FDA docket through the end of March include two breast cancer treatments, a gene therapy for haemophilia, and also an Alzheimers drug.
